On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not as good as continuous hormone therapy with regard to a man’s longevity!

After having thought about the startling conclusions of the phase III study I wrote an additional post about my personal decision to continue current plans to remain on intermittent hormone therapy.

My Current Personal Take on Intermittent Hormone Therapy for Prostate Cancer

Today, Dr. S Meyers posted a video discussing this very same topic. Dr. Meyer’s conclusions were consistent with mine, but of course he is much more eloquent then I am capable of being.

I highly recommend that you watch the video, which can be seen at:

It is very comforting to see that he has drawn the same conclusion that I have; I continue to plan on remaining on an intermittent hormone therapy schedule.

Joel T. Nowak, M.A., M.S.W.